Transforming growth factor-beta (TGF-β), a well-known morphogen, is recognized for its role in regulating growth and ...

A research team from the School of Chinese Medicine in the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) ...

IO Biotech announced promising findings regarding a novel peptide vaccine designed to counter the immunosuppressive effects of Transforming Growth Factor Beta (TGF-β) in solid tumors. The ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

Among these factors, the transforming growth factor (TGF)-β family is important in both lineage selection and progression of differentiation of most, if not all, cell and tissue types.

Agomab Therapeutics NV (‘Agomab’) today announced positive interim results from 44 patients completing treatment in the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal ...

Transforming Growth Factor Beta (TGF-β) is a key immune-suppressive factor in the tumor microenvironment (TME) of most solid tumors, often limiting the efficacy of various immune-oncology therapies.

The research team led by Professor Chen Haiyong (middle) discovers a mechanism of C-reactive protein that exacerbates inflammation in diabetic kidney ...

A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both ...